Photodiagnosis and Photodynamic Therapy
Volume 6, Issue 2 , Pages 97-104 , June 2009

Pharmacokinetics and biodistribution of Photolon® (Fotolon®) in intact and tumor-bearing rats

  • S.V. Shliakhtsin, MSc

      Affiliations

    • RUE “Belmedpreparaty”, 220007 Minsk, Fabritsiusa str. 30, Belarus
    • Tel.: +375 17 220 39 40; fax: +375 17 220 39 40.
    • Corresponding Author InformationCorresponding author at: Department of Pharmacology and Toxicology of RUE “Belmedpreparaty”, 220007 Minsk, Fabritsiusa str. 30, Belarus. Tel.: +375 17 220 39 40; fax: +375 17 220 31 42.
    • ,
  • T.V. Trukhachova

      Affiliations

    • RUE “Belmedpreparaty”, 220007 Minsk, Fabritsiusa str. 30, Belarus
    • Tel.: +375 17 220 31 42; fax: +375 17 220 31 42.
    • ,
  • H.A. Isakau

      Affiliations

    • RUE “Belmedpreparaty”, 220007 Minsk, Fabritsiusa str. 30, Belarus
    • Tel.: +375 17 220 39 40; fax: +375 17 220 39 40.
    • ,
  • Y.P. Istomin

      Affiliations

    • N.N. Alexandrov National Cancer Centre of Belarus, 223040 Minsk, p.o. Lesnoy-2, Belarus
    • Tel: +375 17 220 39 40.

References 

  1. Henderson BW, Dougherty TJ. How does photodynamic therapy work?. J Photochem Photobiol B. 1992;55:145–157
  2. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part three—photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiag Photodynam Ther. 2005;2:91–106
  3. Freitas I. Lipid accumulation: the common feature to photosensitizer retaining in normal and malignant tissues. J Photochem Photobiol B. 1990;7(November (2–4)):359–361
  4. Moan J, Peng Q, Sorensen R. The biophysical foundations of photodynamic therapy. Endoscopy. 1998;4:387–391
  5. Andrejevic Blant S, Ballini JP, van den Bergh H, Fontolliet Ch, Wagnières G, Monnier Ph. Time-dependent biodistribution of tetra(m-hydroxyphenyl)chlorin and benzoporphyrin derivative monoacid ring A in the hamster model: comparative fluorescence microscopy study. J Photochem Photobiol B. 2000;71(3):333–340
  6. Schastak S, Jean B, Handzel R, et al. Improved pharmacokinetics, biodistribution and necrosis in vivo using a new near infra-red photosensitizer: tetrahydroporphyrin tetratosylat. J Photochem Photobiol B. 2005;78:203–213
  7. Rovers JP, Saarnak AE, de Jode M, Sterenborg HJCM, Terpstra OT, Grahn MF. Biodistribution and bioactivity of tetra-pegylated meta-tetra(hydroxyphenyl)chlorin compared to native meta-tetra(hydroxyphenyl)chlorin in a rat liver tumor model. J Photochem Photobiol B. 2000;71(2):210–217
  8. Cheung R, Solonenko M, Busch TM, et al. Correlation of in vivo photosensitizer fluorescence and photodynamic-therapy-induced depth of necrosis in a murine tumor model. J Biomed Optic. 2005;8(2):248–252
  9. Stewart F, Baas P, Star W. What does photodynamic therapy have to offer radiation oncologists (or their cancer patients)?. Radiother Oncol. 1998;48:233–248
  10. Isakau HA, Parkhats MV, Knyukshto VN, Dzhagarov BM, Petrov EP, Petrov PT. Toward understanding the high PDT efficacy of chlorine e6–polyvinylpyrrolidone formulations: Photophysical and molecular aspects of photosensitizer–polymer interaction in vitro. J Photochem Photobiol B. 2008;92:165–174
  11. Isakau HA, Trukhacheva TV, Petrov PT. Isolation and identification of impurities in chlorin e6. J Pharmaceut Biomed Anal. 2007;45:20–29
  12. Chin WW, Heng PW, Thong PS, et al. Improved formulation of photosensitizer chlorin e6 polyvinylpyrrolidone for fluorescence diagnostic imaging and photodynamic therapy of human cancer. Eur J Pharm Biopharm. 2008;69(3):1083–1093Epub 2008, Mar 10
  13. Parkhats MV, Knyukshto VN, Isakov GA, et al. Spectral-luminescent studies of the photosensitizer Photolon® in model systems and in blood of oncological patients. J Appl Spectroscop. 2003;70(6):816–821
  14. Trukhachova TV, Shliakhtsin SV, Isakau GA, et al. New aspects of clinical application of PDT with Photolon®. Book of abstracts of the 7-th international simposium on photodynamic therapy and photodiagnosis in clinical practice. Brixen; 2008;CT-03
  15. Shliakhtsin SV, Trukhachova TV, Isakau GA, Istomin YP. Application of the method of vital in vivo fluorescence intensity measurement in biological tissues for pharmacokinetic studies of different chlorin-based photosensitizers. Biomed Chem. 2009;(2):
  16. Ronn AM, Batti J, Lee CJ, et al. Comparative biodistribution of meta-tetra(hydroxyphenyl)chlorin in multiple species: clinical implications for photodynamic therapy. Lasers Surg Med. 1997;20(4):437–442
  17. Bossu E, A’amar O, Parache RM, et al. Determination of the maximal tumor/normal skin ratio after HPD or mTHPC administration in hairless mouse (SKH1) by fluorescence spectroscopy-non invasive method. Anti Cancer Drug. 1997;8:67–72
  18. Cramers P, Ruevekamp M, Oppelnar H, Dalesio O, Baas P, Stewart FA. Foscan uptake and tissue distribution in relation to photodynamic efficacy. Br J Cancer. 2003;88:283–290
  19. Rosenthal M, Kavar B, Hill J, et al. Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin. J Clin Oncol. 2001;19(January (2)):519–524
  20. Stummer W, Stocker S, Novotny A, et al. In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid. J Photochem Photobiol. 1998;45:160–169
  21. Foscan. European Public Assessment Report, Revision 10 - Published by EMEA 12/08/08.
  22. Gyneatullin RU, Ismagilova ST, Eremeev DV, Astahova LN, Ignat’eva EN. Morphologic changes in brain tissues after photodynamic therapy of malignant tumors reproduced in rats (an experimental study). Bull Novel Med Technol. 2008;3:64–85(article in Russian)

PII: S1572-1000(09)00034-9

doi: 10.1016/j.pdpdt.2009.04.002

Photodiagnosis and Photodynamic Therapy
Volume 6, Issue 2 , Pages 97-104 , June 2009

Article Tools

* Image Usage & Resolution